Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca, Inc. announced updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, showing promising monotherapy responses and tolerability in KRAS-mutant solid tumors, including pancreatic cancer. The company is advancing towards registration-enabling Phase 3 trials in lung and pancreatic cancers, with combination st…